Alector begins Phase 1 clinical trials for Alzheimer’s treatment
Alector, an early-stage biotechnology firm that pioneers immuno-neurology (INO) and innate immune-oncology has announced the start of the first Phase 1 human trial for AL044. The study is investigating AL044’s safety profile, its pharmacokinetics and pharmacodynamics as well as the engagement of target in healthy adults.
Longevity. Technology: Alector, headquartered in South San Francisco, California is working to create an unmatched pipeline for novel potential medicines, based on insights from immunology, neuroscience and human genetics. Alector’s therapeutic candidates harness the body’s natural ability to heal. The company is also pioneering immunoneurology and innate immune-oncology.
Immuno-neurology focuses on immune dysfunction, which is the root cause of many pathologies and degenerative brain disorders. Alector has developed a portfolio of programs for the innate immune system that are designed to repair genetic mutations causing brain immune system dysfunction and rejuvenated immune cell to counteract emerging pathologies. Alector’s immunoneurology product candidate are supported by biomarkers, and target genetically-defined patient populations with frontotemporal degeneration and Alzheimer’s.
Source:
Alector initiates Phase 1 clinical trial for treatment of Alzheimer’s
